IMDX vs LH
IMDX: iMDx develops decentralized molecular diagnostic kits for transplant organ rejection monitoring using donor-derived cell-free DNA biomarkers, enabling in-house testing at hospitals rather than centralized lab services. LH: A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities.
Side-by-side fundamentals
| Metric | IMDX | LH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.99 | $281.46 | |
| Market cap as of 2026-07-23 | $165M | $23.1B | |
| P/E as of 2026-07-23 | n/a | 24.51 | |
| PEG as of 2026-07-23 | n/a | 2.76 | |
| Net margin as of 2026-07-23 | -2454.6% | +6.7% | LH higher |
| Gross margin as of 2026-07-23 | +51.3% | +28.8% | IMDX higher |
| Operating margin as of 2026-07-23 | -2500.7% | +10.2% | LH higher |
| ROE as of 2026-07-23 | -426.7% | +10.9% | LH higher |
| ROA as of 2026-07-23 | -119.1% | +5.1% | LH higher |
| Debt / equity as of 2026-07-23 | 0.92 | 0.73 | LH lower |
| Revenue growth (YoY) as of 2026-07-23 | -49.3% | +7.3% | LH higher |
| Revenue CAGR (3y) SEC XBRL | +61.8% | +5.6% | IMDX higher |
| Dividend yield as of 2026-07-23 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-07-23 | 1.83 | 0.88 | |
| 1-year return as of 2026-07-22 close | +65.0% | +11.7% | IMDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.